Affiliation: CHU de Bordeaux
- Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 studyVirginie Gandemer
Department of Pediatric Hematology, University Hospital of Rennes, Rennes, France
BMC Cancer 9:14. 2009..Here we report the long-term results of the FRALLE 93 study conducted in the era before the use of tyrosine kinase inhibitors...
- Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapyYves Perel
Department of Pediatrics, Onco Hematology Unit, University Hospital, 33076 Bordeaux, France
Pediatrics 109:1170-3. 2002..In some cases of Gaucher's disease, alternative strategies such as fractionated or further increased ERT, gene therapy, or glucosyltransferase inhibitor should be explored...
- Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde EnfantYves Perel
Unité d Onco Hématologie, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, Centres Hospitalo Universitaires de Bordeaux, France
J Clin Oncol 20:2774-82. 2002..To determine whether the use of maintenance therapy (MT) delivered after intensive induction and consolidation therapy confers any advantage in childhood acute myeloid leukemia (AML)...
- Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation statusY Perel
Laboratory of Differentiation and Development Biology, EA DRED 483, University of Bordeaux 2, 146, rue Leo Saignat, 33076 Bordeaux Cedex, France
Br J Cancer 86:117-22. 2002..Finally, our results suggest that galanin influences neuroblastoma growth and development as an autocrine/paracrine modulator. These findings suggest potential critical implications for galanin in neuroblastic tumours development...
- Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative GroupY Perel
Pediatric Onco Hematology Unit, University Hospital, Bordeaux, France
Leukemia 19:2082-9. 2005..6+/-8 vs 59+/-8%; P=0.05), while the 5-year DFS was not significantly different. Exposure to low-dose MT might contribute to clinical drug resistance and treatment failure in relapsing patients...
- [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use]Y Perel
Unité d oncohématologie pédiatrique, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, CHU de Bordeaux, 33076 Bordeaux, France
Arch Pediatr 11:834-42. 2004..Recent advances in understanding the biology and genetics of neuroblastoma will ultimately allow to select poor-risk patients for appropriate future biologically based therapies...
- A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of ageSylvie Monnereau-Laborde
Department of Pediatric Hemato Oncology, CHU Bordeaux, Children s Hospital, Place Amelie Rabat Leon, Bordeaux, France
Pediatr Blood Cancer 57:965-71. 2011..To improve outcome and overall survival (OS) in high-risk neuroblastoma, NB96 induction therapy was intensified using sequential high-dose chemotherapy and autologous stem cell rescue...
- Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocolDominique Valteau-Couanet
Departement de Pediatrie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
J Clin Oncol 23:532-40. 2005..To test the metastatic response rate in stage 4 neuroblastoma, using dose-intensive induction chemotherapy in a multi-institutional setting...
- Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and ImmunologyNathalie Aladjidi
Unité d Onco Hématologie, Departement de Pediatrie, Hopital des Enfants, Groupe Hospitalier Pellegrin, Place Amelie Raba Leon, 33076 Bordeaux, France
J Clin Oncol 21:4377-85. 2003..The goals of this retrospective study were to determine whether these children could be treated successfully with a salvage regimen and to establish the optimal therapeutic strategy...
- High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplificationAnne Laprie
Département d Hémato Oncologie, Hopital des Enfants, Toulouse, France
Cancer 101:1081-9. 2004..The objective of this study was to determine whether systemic and regional, intensified treatment can improve the outcome of children who present with a localized neuroblastoma (NB) with MYCN amplification (MNA)...
- Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003Julie Tandonnet
Bordeaux University and Bordeaux University Hospital, Pediatric Oncology and Hematology Unit, 33076 Bordeaux, France
Pediatr Blood Cancer 54:927-33. 2010..To determine the epidemiology of myeloid leukaemia (ML) in children with Down syndrome (DS) and the efficacy of two approaches, low-dose cytarabine-based regimen (LDC) and standard-dose intensive chemotherapy (SD)...
- Ectopic Cushing's syndrome due to an adrenal ganglioneuromaJean Benoit Corcuff
Department of Nuclear Medicine, CHU Bordeaux, Bordeaux, France
Horm Res Paediatr 73:405-8. 2010..Cushing's syndrome (CS), rare in children, is due to pituitary or, less frequently, to adrenocortical tumors. Ectopic adrenocorticotropin (ACTH) secretion is exceptional...
- Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE)Nathalie Mallol-Mesnard
INSERM U754, IFR69, 16 Avenue Paul Vaillant Couturier, F 94807 Villejuif Cedex, France
Int J Epidemiol 36:110-6. 2007..Elucidating the role of vaccination in the aetiology of childhood acute leukaemia (AL) was therefore included in the objectives of an ongoing national study...
- Rituximab therapy for childhood Evans syndromeBrigitte Bader-Meunier
Assistance Publique Hopitaux de Paris, Service d hématologie oncologie pédiatrique, Hopital Robert Debre, Paris, France
Haematologica 92:1691-4. 2007..4 years (range 0.5-7 years). Steroid therapy was stopped or tapered at 50-100% of the baseline dosage in all long-term responders. Moderate side effects and infection occurred only in 4 and 1 children respectively...
- Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 studyCaroline Oudot
Service d hématologie et oncologie pédiatrique, Hopital Mere Enfant, Limoges, France
J Clin Oncol 26:1496-503. 2008..To identify prognostic factors and to evaluate the outcome of children with acute lymphoblastic leukemia (ALL) failure after induction therapy...
- Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trialsNicolas Boissel
Services d Hématologie Pédiatrique et Adulte, Laboratoire Central d Hématologie, Hopital Saint Louis, France
J Clin Oncol 21:774-80. 2003..To compare pediatric and adult therapeutic practices in the treatment of acute lymphoblastic leukemia (ALL) in adolescents...
- A 22-year French experience with solid tumors in children with Down syndromeDaniel Satgé
Laboratoire d Anatomie Pathologique, Centre Hospitalier, Tulle, France
Pediatr Hematol Oncol 20:517-29. 2003..The treatment of solid tumors in DS is difficult, due to physical and psychological impairments, different pharmacogenetic profile, and associated malformations...
- Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemiaJean Delorme
Department of Pharmacy, Research Unit INSERM No 379, France
J Pediatr Hematol Oncol 25:441-7. 2003..The aim of the current study was to perform an economic evaluation in the same cohort...
- Comparative values of catecholamines and metabolites for the diagnosis of neuroblastomaMaud Monsaingeon
Service de Medecine Nucleaire, Hopital Haut Leveque, 33604 Pessac, France
Eur J Pediatr 162:397-402. 2003..Plotting individual levels (normetanephrine versus vanillylmandelic acid or homovanillic acid) allowed a rapid visual analysis that would have missed only one small low grade non-secreting tumour...
- Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcomePaola Ballerini
Laboratoire d Hematologie, Hopital A Trousseau, INSERM E0210
Haematologica 93:1658-65. 2008..Likewise, the frequency and the prognostic significance in pediatric T-cell acute lymphoblastic leukemia of the newly characterized NUP214-ABL1 fusion transcript is not yet clear...
- An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised childrenDavid Nadal
Division of Infectious Diseases, University Children s Hospital of Zurich, CH 8032 Zurich, Switzerland
J Infect Dis 186:S123-30. 2002..In general, adverse events were not attributable to valacyclovir and were consistent with disease-related expectations and concomitant therapies. Dosage options for using valacyclovir in children are discussed...